Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Author:
Affiliation:
1. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
3. Analysis Group, Inc, Montreal, Canada
4. Analysis Group, Inc, Boston, MA, USA
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1876714
Reference34 articles.
1. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
2. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
3. Revised International Prognostic Scoring System for Myelodysplastic Syndromes
4. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
5. Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis;Blood Advances;2023-11-16
2. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices;Leukemia & Lymphoma;2023-09-07
3. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care;Transplantation and Cellular Therapy;2023-07
4. Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents;Leukemia & Lymphoma;2023-03-08
5. Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States;Advances in Therapy;2022-11-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3